Short-Contact Clobetasol Propionate Shampoo 0.05% Improves Quality of Life in Patients With Scalp Psoriasis

Cutis

Volumn 83, Issue 3, 2009, Pages 157-164

  Tan, Jerry ^a   Thomas, Richard ^b   Wang, Béatrice ^c   Gratton, David ^d   Vender, Ronald ^e   Kerrouche, Nabil ^f   Villemagne, Hervé ^f  

^a Windsor Clinical Research Inc   (Canada)

^b Derm Research at 888 Inc   (Canada)

^c Siena Medical Research Corp   (Canada)

^d International Dermatology Research   (Canada)

^e Dermatrials Research   (Canada)

^f Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; GLUCOCORTICOID;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HISTORY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CLOBETASOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HISTORY, 17TH CENTURY; HUMANS; MALE; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SCALP DERMATOSES; TREATMENT OUTCOME;

EID: 66149125691     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(suppl 2):S57-S61.
2. van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management [published correction appears in Dermatology. 1999;198:222]. Dermatology. 1998;197:326-334.
3. van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200: 292-298.
4. Papp K, Berth-Jones J, Kragballe K, et al. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21:1151-1160.
5. van der Vleuten CJ, van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs. 2001;61:1593-1598.
6. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155: 729-736.
7. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(suppl 1):S59-S69.
8. Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol. 1994;131:678-683.
9. Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol. 1986;15(2, pt 1):246-255.
10. Prawer SE, Katz HI. Guidelines for using superpotent topical steroids. Am Fam Physician. 1990;41:1531-1538.
11. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-224.
12. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2: 89-92.
13. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583.
14. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroids therapy in psoriasis. J Am Acad Dermatol. 2006;55:607-613.
15. David SE, Ahmed Z, Salek MS, et al. Does enough quality of life-related discussion occur during dermatology outpatient consultations? Br J Dermatol. 2005;153: 997-1000.
16. Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol. 2004;3:367-373.
17. Andres P, Poncet M, Farzaneh S, et al. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol. 2006;5:328-332.
18. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16: 31-36.
19. Griffiths CE, Finlay AY, Fleming CJ, et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat. 2006;17:90-95.
20. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
21. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414.
22. Krueger GG, Langley RG, Finlay AY, et al. Patientreported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-1199.
23. Jobling RG. Psoriasis-a preliminary questionnaire study of suffers' subjective experience. Clin Exp Dermatol. 1976;1:233-236.
24. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-936.